Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Dexcom

Health Tech & Medtech · San Diego, United States · Founded 1999 · IPO 2005 Decacorn

Continuous Glucose Monitoring

Valuation
$22B
Market cap · May/2026
Revenue
$4.66B
Latest reported FY
EBITDA
$1.60B
Latest reported FY

Investors

7 investors on Dexcom's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 7 investors entered at this stage
Canaan
Fog City Capital
Windamere Venture Partners
Federated Hermes
RWI Group
St. Paul Venture Capital
Warburg Pincus

Global footprint

Where Dexcom has talent and traffic

AI talent share
0.8% of workforce is AI talent
(69 of 8,542 staff)
Core AI120.14%
Other AI570.67%
Non-AI workforce8,47399.19%
Workforce by country
38 countries with
team presence
🇺🇸 United States60.7%
🇵🇭 Philippines9.7%
🇲🇾 Malaysia8.7%
🇱🇹 Lithuania5.1%
🇬🇧 United Kingdom3.7%
Top 5 of 38 shown
Web traffic by country
2.7M monthly visits
across markets
🇺🇸 United States75.9%
🇩🇪 Germany3.5%
🇬🇧 United Kingdom2.9%
🇨🇦 Canada2.9%
🇮🇳 India1.3%
Top 5 markets shown

Patent intelligence

$858M patent portfolio · 506 active families

Estimated portfolio value
$858M
3.9% of market cap · 1029× the top peer Neko Health ($834k)
506 active patent families
Where Dexcom innovates AnalyteSensor systemBiomedical engineeringElectronicsGlucose Measurement

Where Dexcom concentrates vs peers

Each axis is a top-10 topic across Dexcom and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Dexcom's 9 investments and acquisitions.

Every disclosed deal where Dexcom appeared as a backer or acquirer, 2012–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

9 deals across Dexcom's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Dexcom deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Dexcom's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        9 of 9 deals

        Market sentiment

        What the market is saying about Dexcom

        An AI-synthesized read of the highest-engagement posts about Dexcom on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Dexcom on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.